News

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter “Samsung ...
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and ...
The Pharma Letter14h
Samsung Bioepis partners with Harrow on biosimilars in USA
South Korea’s Samsung Bioepis today announced it has entered into a license, development and commercialization agreement (DCA ...